By Sabela Ojea
Shares of MoonLake Immunotherapeutics climbed after the company said it received positive 24-week results from a trial to treat patients with a chronic inflammatory skin condition.
The stock was up 13% Monday at $61.83.
The clinical-stage biopharmaceutical company said its phase 2 Mira trial showed that maintenance treatment with its sonelokimab treatment led to further improvements in patients with moderate-to-severe hidradenitis suppurativa.
MoonLake Chief Executive Jorge Santos da Silva said the company is on track to discuss its phase 3 development plans with the Food and Drug Administration by the end of the year.
Write to Sabela Ojea at [email protected]; @sabelaojeaguix
Read the full article here
